Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from August 31, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 29, 2025.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$82.59 Published $90.82 Target $103.94 Window close $104.94 Peak
$80.01 – $81.94Entry zone — fair-value band
$82.59Published — price the day we called it
$90.82Target — the price the thesis aimed for
$104.94Peak — highest point inside the window, not a realized return
$103.94Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 74 days.

Peak price
$104.94
peak on November 25, 2025 — not a realized return
Peak gain
+27.1%
peak, from the publication price
Window close
$103.94
end-of-window price, context only
Days to target
74
Window
August 31, 2025 – November 29, 2025

The thesis — published August 31, 2025

Predicted growth
+12%
over the measurement window
Target price
$90.82
the price the thesis aimed for
Entry zone
$80.01 – $81.94
the fair-value band we waited for
Price at publication
$82.59
published August 31, 2025
Confidence
62%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck offers steady money from its core drugs while moving new treatments forward. The first patient in the HERTHENA-Breast04 Phase 3 study has been treated, a clear event that keeps investors watching. The share price looks to be stabilizing and inching up, so buying in steps makes sense. Over the next 1 to 3 months, large drug makers are in favor. A clear pickup in buying strength would be a good sign to add. We expect calm, gradual gains.

Primary drivers

  • A key step reached in a major late-stage study that can guide approval
  • Reliable cash coming in and a steady dividend that softens market swings
  • Share price appears stable and slowly improving after a flat period
  • Investor interest is strong, with more trading activity than usual

How it played out

MRK: target reached in 74 days

Lyra published MRK on 2025-08-31 at 82.59. The thesis expected 12% growth toward 90.82 over a short-term window. It pointed to steady core-drug revenue, progress in a late-stage study, a stable share price that was slowly improving, stronger trading activity, and a steady dividend.

Inside the 2025-08-31 to 2025-11-29 window, MRK rose past the target. The peak was 104.94 on 2025-11-25, with a peak gain of 27.1%. The target was reached in 74 days. The stock ended at 103.94. The published thesis played out.

What happened during the window

On September 19, 2025, Merck said the FDA approved KEYTRUDA QLEX for subcutaneous use in adults across most solid tumor indications for KEYTRUDA. This was an announced company event, not an explanation of the stock move.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals